Edem Agamah, MD

Edem Agamah, MD

Professor, Hematology/Oncology, Department of Internal Medicine
Internal Medicine
Languages:
English, Ewe

    About me

    Specializes in:

    • Hematology
    • Oncology
    • Blood Disorders

     

    Gender

    Male

    Additional languages spoken

    Ewe

    Education & training

    Positions
    Oncologist
    Hematologist
    Board Certifications
    Medical Oncology
    Internal Medicine
    Medical School
    University of Ghana Medical School, Accra, Ghana
    Residency
    Korle Bu Teaching Hospital, Accra, Ghana - Hematology, St. Francis Hospital, Evanston, IL - Internal Medicine
    Fellowship
    University of Chicago, Chicago, IL - Hematology/Oncology

    Research

    Research Interests
    Genetic Epidemiology, Breast Cancer and Colon Cancer

    Publications

    Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators.  Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.  N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14.

    Lerario AM, Worden FP, Ramm CA, Hsseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K, Hammer GD. The Combination of insulin-like growth factor receptor 1 (IGFR) antibody      cixutumumab and mitotane as a first line therapy for patient with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI sponsored trial.  Horm Cancer. 2014 Aug; 5 (4) 232-9

    Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ,  Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL  Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78 (1) 76-80

    Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, Stadler WM, Vokes EE. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.  Invest New Drug. 2012 Feb; 30 (1): 382-6

    Nimeiri, H , Oza  A, Morgan R, Huo D, Elit L, Knost J, Wade J, Agamah E, Vokes E, Fleming G A phase II Study of Sorafenib in Advanced Uterine Carcinoma/Carcinosarcoma: A Trial of the Chicago, PMH and California Phase II Consortia.  Gynecol Oncol. 2010 Apr; 117 (1) 37-40

    The Combination of insulin-like growth factor receptor 1 (IGFR) antibody cixutumumab and mitotane as a first line therapy for patient with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI sponsored trial; Cediranib in patients with malignant mesothelioma; Gemcitabine plus sorafenib in patients with advanced pancreatic cancer; A phase II Study of Sorafenib in Advanced Uterine Carcinoma/Carcinosarcoma; and A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma